• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Understanding the function and dysfunction of the immune system in lung cancer: the role of immune checkpoints

    2015-11-26 07:43:42NikiKarachaliouMariaGonzalezCaoCristinaTeixidSantiagoViteriDanielaMoralesEspinosaMariacarmelaSantarpiaRafaelRosell
    Cancer Biology & Medicine 2015年2期

    Niki Karachaliou, Maria Gonzalez Cao, Cristina Teixidó, Santiago Viteri, Daniela Morales-Espinosa, Mariacarmela Santarpia, Rafael Rosell,,4,5,6

    1Instituto Oncológico Dr Rosell, Quiron Dexeus University Hospital, Barcelona 08028, Spain;2Pangaea Biotech, Barcelona 08028, Spain;3Medical Oncology Unit, Human Pathology Department, University of Messina, Messina 98122, Italy;4Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona 08916, Spain;5Molecular Oncology Research (MORe) Foundation, Barcelona 08028, Spain;6Germans Trias i Pujol Health Sciences Institute and Hospital, Campus Can Ruti 08916, Spain

    REVIEW

    Understanding the function and dysfunction of the immune system in lung cancer: the role of immune checkpoints

    Niki Karachaliou1, Maria Gonzalez Cao1, Cristina Teixidó2, Santiago Viteri1, Daniela Morales-Espinosa1, Mariacarmela Santarpia3, Rafael Rosell1,2,4,5,6

    1Instituto Oncológico Dr Rosell, Quiron Dexeus University Hospital, Barcelona 08028, Spain;2Pangaea Biotech, Barcelona 08028, Spain;3Medical Oncology Unit, Human Pathology Department, University of Messina, Messina 98122, Italy;4Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona 08916, Spain;5Molecular Oncology Research (MORe) Foundation, Barcelona 08028, Spain;6Germans Trias i Pujol Health Sciences Institute and Hospital, Campus Can Ruti 08916, Spain

    Survival rates for metastatic lung cancer, including non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), are poor with 5-year survivals of less than 5%. The immune system has an intricate and complex relationship with tumorigenesis; a groundswell of research on the immune system is leading to greater understanding of how cancer progresses and presenting new ways to halt disease progress. Due to the extraordinary power of the immune system—with its capacity for memory, exquisite specificity and central and universal role in human biology—immunotherapy has the potential to achieve complete, long-lasting remissions and cures, with few side effects for any cancer patient, regardless of cancer type. As a result, a range of cancer therapies are under development that work by turning our own immune cells against tumors. However deeper understanding of the complexity of immunomodulation by tumors is key to the development of effective immunotherapies, especially in lung cancer.

    Lung cancer; immunotherapy; immune checkpoint; program death-ligand 1 (PD-L1); program death-1 (PD-1)

    Introduction

    Lung cancer is one of the leading causes of cancer-related death globally. Non-small cell lung cancer (NSCLC) is the most common type, accounting for nearly 85% of all newly diagnosed cases1. Most patients with NSCLC either present with metastatic disease or experience disease recurrence despite undergoing treatment for seemingly localized disease, underscoring the systemic nature of this disease. Cytotoxic chemotherapy regimens developed over the past few decades have produced only modest improvements in survival in metastatic NSCLC. A small subset of patients with tumors driven by activating mutations in the gene encoding epidermal growth factor receptor (EGFR) or rearrangements in the gene coding for anaplastic lymphoma kinase (ALK) benefit substantially from specific targeted therapies2-4. However, most of these patients eventually succumb to tumor progression within a few years of diagnosis. Thus therapies that obtain long lasting disease control are urgently needed.

    The immune system plays an important role in controlling and eradicating cancer. Nevertheless, in the setting of malignancy, multiple mechanisms of immune suppression may exist that prevent effective antitumor immunity. Antibody therapy directed against several negative immunologic regulators is currently demonstrating significant success and is likely to become a major component of treatment for patients with a variety of malignancies. Therefore, this review focuses on the role of immune system in cancer and indeed lung cancer.

    What is an immune checkpoint?

    Thymus-derived lymphocytes (T-lymphocytes, T-cells)activation and expansion are necessary for an effective acquired immune response. Spontaneous lymphocytic infiltrates can be consistently observed in a variety of tumors. CD4 T-cells and CD8 T-cells make up the majority of T-lymphocytes. Interferon-γ producing CD8 T cells play an important role in inhibiting and killing tumor cells and impeding tumor growth. Interleukin-12 and granulocyte-macrophage colony-stimulating factor (GM-CSF) induce the activation of tumor-resident CD8 T effector/memory cells (Tem) followed by cytotoxic CD8 T effector cell expansion, a population that is a potent in situ resource for successful reactivation of systemic antitumor T cell immunity5. Amongst the many factors CD8 T cells produced, interferon-γ seems to be one of most significant cytokines in preventing and suppressing the development of cancers. In addition, the cytotoxic effects of CD8 T cells may also directly mediate death of tumor cells6.

    After being activated and differentiated into distinct effector subtypes, CD4 T-cells play a major role in mediating immune response through the secretion of specific cytokines. These cells have multiple functions, ranging from activation of the cells of the innate immune system, B-lymphocytes, cytotoxic T-cells, as well as non-immune cells, and also play a critical role in suppression of immune reaction. Ongoing studies have identified new subsets of CD4 cells besides the classical T-helper 1 and 2 cells, like T-helper 17, follicular helper T-cell, induced T-regulatory cells (Treg), and the regulatory type 1 cells as well as the potentially distinct T-helper 97. Tregs, originally termed suppressive T-cells, were first described in the early 1970s as thymus-derived lymphocytes that tolerized bone marrowderived lymphocytes to antigenic challenge8,9. Subsequent research demonstrated that T-cells expressing CD4 and CD25 [the alpha chain of interleukin-2 (IL-2) receptor] from tumorbearing mice abrogated tumor rejection10-14. It was 10 years later that Sakaguchi and colleagues ascertained that CD25 could be used to identify these suppressive cells15. Later studies from the same laboratory established the forkhead box P3 (FoxP3) transcription factor as both a key intracellular marker of CD4+CD25+Tregs and a necessary factor for development and proper function of these cells16.

    One of the key attributes is how the T-cells activate and distinguish “self” from “non-self” molecules. A series of positive and negative costimulatory receptors are expressed on a T-cell at variable levels according to the timing and circumstances of the immune response. The efficiency with which CD4 T-cells direct an immune response demands that proper regulatory measures are in place to prevent immune hyperactivation leading to autoimmune disease. This is very important especially for organs like the lungs that have large mucosal and gas-exchanging surfaces which are constantly exposed to the environment17. Such a critical process involves presentation of antigens to T-cells by antigen presenting cells (APC) and is highly regulated by molecules on T-cells and APC as well as tumor and stromal cells, known as immune checkpoints. Recognition of antigenmajor histocompatibility complex (MHC) complexes by the T-cell antigen receptor is not sufficient for activation of na?ve T-cells. Additional costimulatory signals are required and are provided by the engagement of CD28 on the T-cell surface with B7 molecules (CD80 and CD86) on the APC18,19(Figure 1). The role of immune checkpoints is not only to trigger a sufficient immune response but also to inhibit stimulation to ensure the inductive immune response is not excessive. In fact, these immune checkpoints, usually referred to as molecules of inhibitory pathways in the immune system, are crucial for maintaining self-tolerance and modulating physiological immune responses in the periphery, in order to avoid or minimize tissue damage from excess reactions.

    The CD28 family of cell surface receptors [CD28, cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), inducible costimulator (ICOS), program death-1 (PD-1), and B- and T-lymphocyte attenuator (BTLA)] plays a critical role in controlling the adaptive arm of the immune response and controlling T-cell activation. The counterpart (ligand) for CD28 is the “B7 family”, containing B7-1 (CD80) and B7-2 (CD86), which are usually present on APC. Although there is structural similarity between members of the CD28 family, functional heterogeneity is observed. For instance, ligation of CD28 and ICOS promotes T-cell activation, whereas engagement of CTLA-4, PD-1, and BTLA inhibits T-cell activation20. Other regulators of T-cell activation have recently been characterized and may have important roles. These include T-cell immunoglobulin and mucin domain-containing protein 3 (TIM3; also known as HAVCR2), lymphocyte activation gene-3 (LAG-3) and V-domain immunoglobulin suppressor of T-cell activation (VISTA)21-23.

    CTLA-4 is expressed exclusively on T-cells and shares identical ligands (CD80 and CD86) with the T-cell costimulatory receptor CD28. When the T-cell receptor (TCR) is engaged by cognate antigen, CD28 induces T-cell activation. CTLA-4 has a much higher overall affinity for both ligands and inhibits the activation of T-cells by outcompeting CD28 in binding CD80 and CD86. At the same time, CTLA-4 activates the Src homology region 2 domain-containing phosphatase-2 (SHP2) and protein phosphatase 2A (PP2A) and counteracts kinase signals induced by TCR and CD28, sequestrates CD80 and CD86 from CD28 engagement, and actively removes CD80 and CD86 from the APC surface.

    Figure 1 T-cell interaction with aPC and tumor cells: the immune checkpoints CTLa-4 and PD-1/PD-L1. Depicted are various ligand-receptor interactions between T-cells, aPCs and cancer cells that regulate the T-cell response to antigen. activation of T-cells is a two-step process that requires recognition of specific peptides presented by MHC on the surface of cancer cells through their TCR, as well as a co-regulatory signal delivered by the CD28 family of receptors (the so-called immune checkpoints). The co-regulatory signal promotes T-cell clonal expansion, cytokine secretion, and functional activity of the T-cell. In the absence of this signal (even in the presence of a target peptide), T-cells fail to respond effectively and are functionally inactivated. This is designed as a fail-safe mechanism to ensure that the immune system is activated at the appropriate time in order to limit collateral damage to normal tissue and minimize the possibility of chronic autoimmune inflammation. Checkpoint pathways regulate these coregulatory signals and can be either stimulatory (switching T-cells on) or inhibitory (switching them off). CTLa-4 and PD-1 deliver inhibitor signals. CTLa-4 negatively regulates T-cell activation by binding to B7 molecules (CD80/86) on the surface of aPC or tumor cell. Conversely, when these B7 molecules bind to CD28 they generate the opposite effect, activating signals. When PD-1 binds to either of its ligands (PD-L1 or PD-L2), which are primarily expressed within inflamed tissues and the tumor microenvironment, it results in inhibition of T-cell activity. aPC, antigen-presenting cell (dendritic cell, macrophage or any cell that expresses antigen); TCR, T-cell receptor; MHC, major histocompatibility complex.

    PD-1 signaling involves binding to several discrete ligands, including PD-L1 (also known as B7-H1 and CD274) and PDL2 (also known as B7-DC and CD273), as well as to the costimulatory molecule CD80. The PD-1/PD-L1 interaction inhibits T-lymphocyte proliferation, survival and effector functions (cytotoxicity, cytokine release), induces apoptosis of tumor-specific T-cell and promotes differentiation of CD4 T-cells into Tregs and tumor cell resistance to cytotoxic T-lymphocytes (CTL) attack21. Because many tumors are highly infiltrated with Tregs that probably further suppress effector immune responses, blockade of the PD-1 pathway may also enhance antitumor immune responses by diminishing the number and/ or suppressive activity of intratumoral Tregs. Chemnitz et al.24revealed that the ability of PD-1 to block T-cell activation correlates with recruitment of SHP-1 and SHP-2. Indeed, PD-1 has a cytoplasmic immunoreceptor tyrosine based inhibitory motif (ITIM), as well as an immunoreceptor tyrosine-based switch motif (ITSM), and has been found to be capable of recruiting the phosphatases SHP-1 and SHP-2. Recruitment of SHP-1 and SHP-2 to ITIM within the PD-1 cytoplasmic tail inhibits positive signaling events downstream of the TCR, mainly PI3K/AKT activation25.

    SHP-1 and SHP-2 are highly related tyrosine phosphatases that serve very distinct roles in signal transduction. SHP-1 expression is largely confined to hemopoietic cells and is thought to act as a negative regulator of STAT3 and other signaling pathways. SHP1 is encoded by the PTPN6 gene and the regulatory factor X-1 (RFX-1) is one transcription factor that can activate SHP-1 transcription26. SHP-2, in contrast, is widely expressed and generally acts in a positive manner to transduce signals from receptor protein tyrosine kinases. For instance, an established role of SHP-2 in EGFR or ALK signaling is to mediate ERK1/2 activation. However, SHP-2 also has been shown to inhibit the JAK-STAT signaling pathway27-29.

    Immune response and cancer

    Immunotherapies that boost the ability of endogenous T-cells to destroy cancer cells have demonstrated therapeutic efficacy in a variety of human malignancies. In 2010, the field was revitalized by a landmark randomized clinical trial that demonstrated thattreatment with ipilimumab, an antibody targeting CTLA-4, improved overall survival (OS) of patients with metastatic melanoma30. Recent studies have demonstrated that T-cell–based immunotherapies are also effective in a range of other human malignancies. In particular, clinical trials of antibodies that interfere with PD-1 have shown clinical activity in tumor types as diverse as lung, bladder, stomach, renal cell, and head and neck cancer, as well as melanoma and Hodgkin’s lymphoma31.

    T-cells in tumors—the so-called tumor infiltrating lymphocytes (TIL) have been studied intensively over the past years. The first evidence that T-cells could kill tumor cells was provided by L.R. Freedman and colleagues in 197232. Numerous studies suggest a positive prognostic impact of TIL but this still needs to be verified in large multi-center studies33. At present there is very limited knowledge as to why some tumors are heavily infiltrated by T-cells whereas others are not. Studies from the laboratory of Robert Schreiber have suggested the “Three Es of cancer immunoediting”34, or three phases of interaction between tumor and immune system: immune-Elimination of cancer cells, immune Equilibrium between cancer cells and cells of the immune system and immune Escape by cancer cells34. However, this notion is still unclear and TILs display a wide range of different phenotypes. Studies have shown that CD8 T-cells at the tumor site display markers of T-cell exhaustion to a higher extent than T-cells in the blood or from normal adjacent tissue35,36. In melanomas, CD8 and CD4 TILs display high expression of PD-1 and CTLA-4. Furthermore, the PD-1 positive fraction of the TILs displays impaired effector functions35.

    Tumor and PD-L1 expression

    Tumor cells can activate PD-L1 expression via multiple oncogenic signaling pathways involving IFN-γ/JAK2/IFN37, PI3K38, ALK/STAT339, MEK/ERK/STAT1, MYD88/TRAF640or exposure to inflammatory cytokines such as IFN-γ41produced by infiltrating immune cells. In breast cancer, PD-L1 expression is strongly associated with proliferative Ki-67 expression and cell cycle progression independent of host PD-142. In human glioma, loss of the tumor suppressor gene phosphatase and tensin homolog (PTEN) has been correlated with enhanced PD-L1 expression38. Similarly, in colorectal cancer, miR-20b, -21 and 130 inhibited PTEN expression, resulting in PD-L1 overexpression43. T-cell lymphoma cells carrying the oncogenic nucleophosmin (NPM)-ALK, involved in malignant transformation, induce high levels of PD-L1 expression via STAT3 and ERK activation39,44.

    Abnormal expression of PD-L1 has been described in 19%-100% of NSCLCs and is associated with poor prognosis45-48. Reliable biomarkers associated with response to PD-1 blockade remain poorly understood49. Simultaneous activation of KRAS and inactivation of serine-threonine kinase 11 (also known as LKB1) induce lung squamous cell carcinoma formation50. Activation of the EGFR pathway might be involved in suppressing the immune response in murine melanoma models either through activating Tregs cells or reducing the levels of the T-cell chemoattractant49. Interestingly, Akbay et al.51found that activation of the EGFR pathway induced PD-L1 expression to help NSCLC tumors to remodel tumor microenvironment to trigger immune escape and link tumor response to PD-1 inhibition. This role of EGFR signaling was independent of its effects on cell proliferation and survival, suggesting that the combination of PD-1 blockade with EGFR TKIs may be a promising therapeutic strategy to extend the duration of treatment response and delay development of resistance to EGFR inhibitors51. D’Incecco et al.52found that PD-L1 positive NSCLC patients had higher sensitivity to EGFR-TKIs, longer time to progression and OS than PD-1 negative patients. They also reported that PD-L1 positive status was significantly associated with presence of EGFR mutations52. In the study of Azuma et al.53, inhibition of EGFR signaling by erlotinib downregulated surface expression of PD-L1 in EGFR mutationpositive NSCLC cells, but not in the EGFR wild-type cells. In contrast, Mu et al.47found no significant correlation between PD-L1 expression and EGFR/KRAS/BRAF/ALK expression in stage I NSCLC patients, similar to Zhang et al.54, who found no significant relationship between PD-L1 expression and EGFR/KRAS expression in lung adenocarcinoma. At the 2015 ASCO Annual Meeting, median progression free survival (PFS) and OS for EGFR TKIs were similar between PD-L1 positive and PD-L1 negative patients at baseline. Also, median PFS for ALK TKIs was similar in PD-L1 positive and PD-L1 negative patients at baseline, but median OS was shorter among PD-L1 positive patients. Expression was dynamic, with changes in PDL1 expression and immune infiltrates observed over time and/or following treatment55.

    Cancer immunotherapy in clinical practice

    Three new immune checkpoint agents have now been approved by the U.S. Food and Drug Administration (FDA) for the treatment of melanoma31. The list of cancers that can be targeted with immunotherapy is growing and there are high expectations that immune checkpoint agents will also be approved for treatment of patients with lung, kidney, bladder and prostate cancer, as well as lymphoma and many other tumor types. Immune checkpoints inhibitors target molecules that regulateT cells rather than the T cells themselves in order to reverse the activation of inhibitory pathways and release antitumor T-cell responses.

    Two phase III clinical trials with anti-CTLA-4 (ipilimumab) were conducted in patients with advanced melanoma and demonstrated improved OS with the drug30,56. Anti-CTLA-4, having more mature survival data than other agents, leads to durable clinical responses that can last a decade and more, but only in a fraction of patients. A recent analysis indicated survival of 10 years or more for a subset of patients57. Ipilimumab was approved in 2011.

    Pembrolizumab and nivolumab, two antibodies against PD-1 were approved in September and December 2014, respectively, for treatment of metastatic melanoma31. A phase I clinical trial with pembrolizumab led to response rates of almost 38% in patients with advanced melanoma, and a subsequent study reported an overall response rate of 26% in patients who had progressive disease after prior ipilimumab treatment58,59. In a phase III trial, nivolumab improved OS of patients with metastatic melanoma in comparison with dacarbazine chemotharpy59. According to the results of the CheckMate 057 trial presented at the 2015 ASCO Annual Meeting, nivolumab is the first PD-1 inhibitor to significantly improve OS in comparison with docetaxel, in previously treated patients with advanced non-squamous NSCLC with 27% reduction in risk of death and significantly improved overall response rate. Tumor PD-L1 expression was found to be predictive of nivolumab benefit60. Nivolumab was FDA approved in March 2015 for patients with previously treated advanced or metastatic NSCLC based on a phase III clinical trial which reported an improvement in OS for patients treated with nivolumab as compared to patients treated with docetaxel chemotherapy31. In addition, nivolumab was recently found to be the first PD-1 inhibitor to demonstrate a survival benefit versus standard-of-care docetaxel in previously treated patients with advanced squamous NSCLC with 41% reduction in risk of death; benefit was independent of PD-1 expression61.

    Biomarkers and response to immunotherapy; neoantigen load as a potential biomarker for cancer immunotherapy

    There are ongoing studies to identify predictive biomarkers to select patients for treatment with a particular agent, but this is complicated by the complexity of the immune response. The expression of PD-L1 in cancer cells is an obvious candidate as it can directly turn off the immune response by inhibiting the activity of cytotoxic T-cells infiltrating the tumor. However, PDL1 expression in tumor cells has little predictive power. Tumeh et al.62established a set of conditions that correlates with good response of patients with melanoma to pembrolizumab therapy. These include the presence of cytotoxic T-cells in the tumor, the expression of PD-L1 and PD-1 in immune cells in the tumor margin, and less complexity (in terms of antigen receptors) in the tumor T-cell population62. Herbst et al.63also observed that PDL1 expression in immune cells is a good biomarker of response to immunotherapy.

    Blockade of CTLA-4 and PD-1 has resulted in durable responses in many patients30,64. However it remains unclear why some have only transient or no response. A major hurdle in tumor immunotherapy is the fact that mechanisms of selftolerance that prevent autoimmunity also impair T-cell responses against tumors. The nature of the antigens that allow the immune system to distinguish cancer cells from non-cancer cells has long remained obscure. Every tumor contains hundreds or thousands of somatic mutations and certain types of tumors display many more or less mutations. Melanomas and lung cancers are the outliers and contain approximately 200 nonsynchronous mutations per tumor, associated with environmental exposure to ultraviolet light and smoking65. It seems that response to immune-based drugs may be written in tumor DNA. Tumors with a high somatic mutation load are more likely to respond to immunotherapy as, in theory, they would have a higher diversity of neoantigens that can trigger an immune response when the CTLA-4/PD-1 inhibition is bypassed. In NSCLC patients treated with anti–PD-1, mutational load shows a strong correlation with clinical response66. Likewise, in melanoma patients treated with ipilimumab, long-term benefit is also associated with a higher mutational load, although the effect appears less profound in this setting67. In the study of Snyder and colleagues67, mutational burden was higher in patients with a sustained clinical benefit than in those without. While the data indeed show that high mutation load correlates with responsiveness to therapy in many cases, surprisingly some tumors with a high load of somatic mutations fail to respond to checkpoint blockade. Therefore, quality not quantity of mutations has the strongest predictive value. A number of tetrapeptide sequences common to patients with sustained clinical benefit, but completely absent in patients with a minimal or no benefit, were homologous to viral and bacterial antigens67. An interesting interpretation of these data is that the neoantigenspecific T-cell response is preferentially directed toward a subset of mutant sequences, something that could facilitate bioinformatic identification of neoantigens for therapeutic targeting68. However, other studies have not found the profoundbias toward these tetrapeptide signatures that would be predicted if their role was central to the tumor-specific T-cell response, meaning that the identified tetrapeptide motifs may play a different role69.

    Conclusion

    Cancer immunotherapy relies on the ability of the immune system to identify and destroy tumor cells and elicit a longlasting memory of this interaction. Various strategies are being developed to enhance anti-tumor immune responses, with a recent focus on antagonists of inhibitory signaling pathways to overcome immune checkpoints. Existing therapies are also being investigated for their ability to induce an anti-tumor immune response, something which could lead to administration of combination therapies providing a more efficacious and durable response. However, there are issues that remain to be understood. Soon many cancer immunotherapies will be made available, many combinations will be possible, and this choice will be quite challenging from a clinical, regulatory, and reimbursement perspective. Biomarkers and companion diagnostics may also play a big role in guiding the way, as will a deepening understanding of immunotherapy mechanisms and cancer response.

    Conflict of Interest Statement

    No potential conflicts of interest are disclosed.

    References

    1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9-29.

    2. Rosell R, Bivona TG, Karachaliou N. Genetics and biomarkers in personalisation of lung cancer treatment. Lancet 2013;382:720-731.

    3. Rosell R, Karachaliou N, Wolf J, Ou SH. ALK and ROS1 nonsmall-cell lung cancer: two molecular subgroups sensitive to targeted therapy. Lancet Respir Med 2014;2:966-968.

    4. Rosell R. Dynamic Evolution of ALK Positive Non-Small Cell Lung Cancers and Management of Associated Brain Metastases [podcast]. J Clin Oncol 2015. [Epub ahead of print].

    5. Kilinc MO, Gu T, Harden JL, Virtuoso LP, Egilmez NK. Central role of tumor-associated CD8+ T effector/memory cells in restoring systemic antitumor immunity. J Immunol 2009;182:4217-4225.

    6. Zamarron BF, Chen W. Dual roles of immune cells and their factors in cancer development and progression. Int J Biol Sci. 2011;7:651-658.

    7. Luckheeram RV, Zhou R, Verma AD, Xia B. CD4+T cells: differentiation and functions. Clin Dev Immunol 2012;2012:925135.

    8. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005;5:263-274.

    9. Kryczek I, Wei S, Gong W, Shu X, Szeliga W, Vatan L, et al. Cutting edge: IFN-gamma enables APC to promote memory Th17 and abate Th1 cell development. J Immunol 2008;181:5842-5846.

    10. Gershon RK, Kondo K. Infectious immunological tolerance. Immunology 1971;21:903-914.

    11. Gershon RK, Kondo K. Cell interactions in the induction of tolerance: the role of thymic lymphocytes. Immunology 1970;18:723-737.

    12. Berendt MJ, North RJ. T-cell-mediated suppression of antitumor immunity. An explanation for progressive growth of an immunogenic tumor. J Exp Med 1980;151:69-80.

    13. Bursuker I, North RJ. Generation and decay of the immune response to a progressive fibrosarcoma. II. Failure to demonstrate postexcision immunity after the onset of T cell-mediated suppression of immunity. J Exp Med 1984;159:1312-1321.

    14. North RJ, Bursuker I. Generation and decay of the immune response to a progressive fibrosarcoma. I. Ly-1+2- suppressor T cells down-regulate the generation of Ly-1-2+ effector T cells. J Exp Med 1984;159:1295-1311.

    15. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995;155:1151-1164.

    16. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003;299:1057-1061.

    17. Heikkinen T, J?rvinen A. The common cold. Lancet 2003;361:51-59.

    18. Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol 2005;23:515-548.

    19. Townsend SE, Allison JP. Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science 1993;259:368-370.

    20. Riley JL, June CH. The CD28 family: a T-cell rheostat for therapeutic control of T-cell activation. Blood 2005;105:13-21.

    21. Nirschl CJ, Drake CG. Molecular pathways: coexpression of immune checkpoint molecules: signaling pathways and implications for cancer immunotherapy. Clin Cancer Res 2013;19:4917-4924.

    22. Ngiow SF, von Scheidt B, Akiba H, Yagita H, Teng MW, Smyth MJ. Anti-TIM3 antibody promotes T cell IFN-γ-mediated antitumorimmunity and suppresses established tumors. Cancer Res 2011;71:3540-3551.

    23. Wang L, Rubinstein R, Lines JL, Wasiuk A, Ahonen C, Guo Y, et al. VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses. J Exp Med 2011;208:577-592.

    24. Chemnitz JM, Parry RV, Nichols KE, June CH, Riley JL. SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J Immunol 2004;173:945-954.

    25. Yokosuka T, Takamatsu M, Kobayashi-Imanishi W, Hashimoto-Tane A, Azuma M, Saito T. Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2. J Exp Med 2012;209:1201-1217.

    26. Su JC, Chiang HC, Tseng PH, Tai WT, Hsu CY, Li YS, et al. RFX-1-dependent activation of SHP-1 inhibits STAT3 signaling in hepatocellular carcinoma cells. Carcinogenesis 2014;35:2807-2814.

    27. Tang TL, Freeman RM Jr, O’Reilly AM, Neel BG, Sokol SY. The SH2-containing protein-tyrosine phosphatase SH-PTP2 is required upstream of MAP kinase for early Xenopus development. Cell 1995;80:473-483.

    28. Bennett AM, Hausdorff SF, O’Reilly AM, Freeman RM, Neel BG. Multiple requirements for SHPTP2 in epidermal growth factormediated cell cycle progression. Mol Cell Biol 1996;16:1189-1202.

    29. Lehmann U, Schmitz J, Weissenbach M, Sobota RM, Hortner M, Friederichs K, et al. SHP2 and SOCS3 contribute to Tyr-759-dependent attenuation of interleukin-6 signaling through gp130. J Biol Chem 2003;278:661-671.

    30. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-723.

    31. Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348:56-61.

    32. Freedman LR, Cerottini JC, Brunner KT. In vivo studies of the role of cytotoxic T cells in tumor allograft immunity. J Immunol 1972;109:1371-1378.

    33. Fridman WH, Pagès F, Sautès-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012;12:298-306.

    34. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol 2004;22:329-360.

    35. Ahmadzadeh M, Johnson LA, Heemskerk B, Wunderlich JR, Dudley ME, White DE, et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 2009;114:1537-1544.

    36. Wang QJ, Hanada K, Robbins PF, Li YF, Yang JC. Distinctive features of the differentiated phenotype and infiltration of tumorreactive lymphocytes in clear cell renal cell carcinoma. Cancer Res 2012;72:6119-6129.

    37. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002;8:793-800.

    38. Parsa AT, Waldron JS, Panner A, Crane CA, Parney IF, Barry JJ, et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med 2007;13:84-88.

    39. Marzec M, Zhang Q, Goradia A, Raghunath PN, Liu X, Paessler M, et al. Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). Proc Natl Acad Sci U S A 2008;105:20852-20857.

    40. Liu J, Hamrouni A, Wolowiec D, Coiteux V, Kuliczkowski K, Hetuin D, et al. Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. Blood 2007;110:296-304.

    41. Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 2012;4:127ra37.

    42. Ghebeh H, Tulbah A, Mohammed S, Elkum N, Bin Amer SM, Al-Tweigeri T, et al. Expression of B7-H1 in breast cancer patients is strongly associated with high proliferative Ki-67-expressing tumor cells. Int J Cancer 2007;121:751-758.

    43. Zhu J, Chen L, Zou L, Yang P, Wu R, Mao Y, et al. MiR-20b, -21, and -130b inhibit PTEN expression resulting in B7-H1 over-expression in advanced colorectal cancer. Hum Immunol 2014;75:348-353.

    44. Yamamoto R, Nishikori M, Tashima M, Sakai T, Ichinohe T, Takaori-Kondo A, et al. B7-H1 expression is regulated by MEK/ ERK signaling pathway in anaplastic large cell lymphoma and Hodgkin lymphoma. Cancer Sci 2009;100:2093-2100.

    45. Hirahara K, Ghoreschi K, Yang XP, Takahashi H, Laurence A, Vahedi G, et al. Interleukin-27 priming of T cells controls IL-17 production in trans via induction of the ligand PD-L1. Immunity 2012;36:1017-1030.

    46. Konishi J, Yamazaki K, Azuma M, Kinoshita I, Dosaka-Akita H, Nishimura M. B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res 2004;10:5094-5100.

    47. Mu CY, Huang JA, Chen Y, Chen C, Zhang XG. High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Med Oncol 2011;28:682-688.

    48. W?lfle SJ, Strebovsky J, Bartz H, S?hr A, Arnold C, Kaiser C, et al.PD-L1 expression on tolerogenic APCs is controlled by STAT-3. Eur J Immunol 2011;41:413-424.

    49. Pivarcsi A, Müller A, Hippe A, Rieker J, van Lierop A, Steinhoff M, et al. Tumor immune escape by the loss of homeostatic chemokine expression. Proc Natl Acad Sci U S A 2007;104:19055-19060.

    50. Xu C, Fillmore CM, Koyama S, Wu H, Zhao Y, Chen Z, et al. Loss of Lkb1 and Pten leads to lung squamous cell carcinoma with elevated PD-L1 expression. Cancer Cell 2014;25:590-604.

    51. Akbay EA, Koyama S, Carretero J, Altabef A, Tchaicha JH, Christensen CL, et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov 2013;3:1355-1363.

    52. D’Incecco A, Andreozzi M, Ludovini V, Rossi E, Capodanno A, Landi L, et al. PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients. Br J Cancer 2015;112:95-102.

    53. Azuma K, Ota K, Kawahara A, Hattori S, Iwama E, Harada T, et al. Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer. Ann Oncol 2014;25:1935-1940.

    54. Zhang Y, Wang L, Li Y, Pan Y, Wang R, Hu H, et al. Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma. Onco Targets Ther 2014;7:567-573.

    55. Gainor JF, Sequist LV, Shaw AT, Azzoli CG, Piotrowska Z, Huynh T, et al. Clinical correlation and frequency of programmed death ligand-1 (PD-L1) expression in EGFR-mutant and ALK-rearranged non-small cell lung cancer (NSCLC). J Clin Oncol 2015;33:abstr 8012.

    56. Robert C, Thomas L, Bondarenko I, O’Day S, Weber J, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364:2517-2526.

    57. Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, et al. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. J Clin Oncol 2015;33:1889-1894.

    58. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013;369:134-144.

    59. Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015;372:320-330.

    60. Paz-Ares L, Horn L, Borghaei H, Spigel DR, Steins M, Ready N, et al. Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC). J Clin Oncol 2015;33:abstr LBA109.

    61. Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med 2015. [Epub ahead of print].

    62. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014;515:568-571.

    63. Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014;515:563-567.

    64. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-2454.

    65. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, et al. Signatures of mutational processes in human cancer. Nature 2013;500:415-421.

    66. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015;348:124-128.

    67. Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 2014;371:2189-2199.

    68. Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science 2015;348:69-74.

    69. Schumacher TN, Kesmir C, van Buuren MM. Biomarkers in cancer immunotherapy. Cancer Cell 2015;27:12-14.

    Cite this article as: Karachaliou N, Cao MG, Teixidó C, Viteri S, Morales-Espinosa D, Santarpia M, Rosell R. Understanding the function and dysfunction of the immune system in lung cancer; the role of immune checkpoints. Cancer Biol Med 2015;12:79-86. doi: 10.7497/ j.issn.2095-3941.2015.0029

    Correspondence to: Rafael Rosell

    E-mail: rrosell@iconcologia.net

    april 15, 2015; accepted June 10, 2015.

    available at www.cancerbiomed.org

    Copyright ? 2015 by Cancer Biology & Medicine

    久久久久国产网址| 看十八女毛片水多多多| 麻豆成人午夜福利视频| av免费在线看不卡| 我的老师免费观看完整版| 亚洲人成网站高清观看| 国产精品一区二区在线不卡| 精华霜和精华液先用哪个| .国产精品久久| 日本欧美视频一区| 免费看av在线观看网站| 亚洲人与动物交配视频| 日本一二三区视频观看| 免费久久久久久久精品成人欧美视频 | 亚洲经典国产精华液单| 女的被弄到高潮叫床怎么办| 各种免费的搞黄视频| 边亲边吃奶的免费视频| 男人狂女人下面高潮的视频| 亚洲综合精品二区| 精品一区在线观看国产| 日本与韩国留学比较| 精品国产一区二区三区久久久樱花 | 久久精品国产亚洲网站| 久久影院123| 亚洲欧美精品自产自拍| 人妻一区二区av| 国产精品麻豆人妻色哟哟久久| 久久影院123| 亚洲欧美精品专区久久| 九九在线视频观看精品| 国产精品人妻久久久久久| 妹子高潮喷水视频| 久久人人爽人人爽人人片va| 亚洲av欧美aⅴ国产| 久久久久国产网址| 在线观看免费视频网站a站| 女性被躁到高潮视频| 一区二区av电影网| 亚洲在久久综合| 国产免费视频播放在线视频| 亚洲国产欧美人成| 精品国产乱码久久久久久小说| 午夜福利网站1000一区二区三区| 成人毛片a级毛片在线播放| 免费高清在线观看视频在线观看| 国产精品成人在线| 精品国产乱码久久久久久小说| 九九久久精品国产亚洲av麻豆| 18禁裸乳无遮挡动漫免费视频| 九色成人免费人妻av| 国产精品人妻久久久影院| 欧美另类一区| 最近中文字幕高清免费大全6| 啦啦啦视频在线资源免费观看| 欧美成人a在线观看| 男男h啪啪无遮挡| 国语对白做爰xxxⅹ性视频网站| 日韩亚洲欧美综合| 狂野欧美白嫩少妇大欣赏| 99热这里只有是精品在线观看| 欧美日韩亚洲高清精品| 欧美日韩亚洲高清精品| 老女人水多毛片| 国产日韩欧美在线精品| 日韩在线高清观看一区二区三区| 免费看光身美女| 国产成人精品福利久久| 在线天堂最新版资源| 22中文网久久字幕| 日日啪夜夜撸| 十分钟在线观看高清视频www | 在线观看一区二区三区激情| 麻豆成人av视频| 伦理电影大哥的女人| 国产免费一级a男人的天堂| 五月伊人婷婷丁香| 亚洲欧美成人综合另类久久久| 黑人高潮一二区| 男女国产视频网站| 久久精品久久精品一区二区三区| 欧美日韩国产mv在线观看视频 | 人体艺术视频欧美日本| 精品人妻偷拍中文字幕| 日韩av不卡免费在线播放| 日本色播在线视频| 我的女老师完整版在线观看| 18禁裸乳无遮挡动漫免费视频| 偷拍熟女少妇极品色| 深爱激情五月婷婷| 99久久精品国产国产毛片| 中文乱码字字幕精品一区二区三区| 国产精品99久久99久久久不卡 | 你懂的网址亚洲精品在线观看| 亚洲精品,欧美精品| 哪个播放器可以免费观看大片| 夫妻午夜视频| 亚洲高清免费不卡视频| 在线免费观看不下载黄p国产| 国产爽快片一区二区三区| 中文字幕久久专区| 日韩,欧美,国产一区二区三区| 高清黄色对白视频在线免费看 | 在线看a的网站| 国产精品偷伦视频观看了| 亚洲精品日韩av片在线观看| 免费久久久久久久精品成人欧美视频 | 日韩电影二区| 免费人成在线观看视频色| 久久精品国产亚洲av涩爱| 国产精品一区二区在线观看99| 日韩av在线免费看完整版不卡| 亚洲欧洲国产日韩| 伦理电影免费视频| 美女内射精品一级片tv| 在现免费观看毛片| 女的被弄到高潮叫床怎么办| 老女人水多毛片| 在线播放无遮挡| 日本-黄色视频高清免费观看| 91久久精品电影网| 91aial.com中文字幕在线观看| 国产男人的电影天堂91| 国模一区二区三区四区视频| 男人狂女人下面高潮的视频| 午夜视频国产福利| 高清午夜精品一区二区三区| av在线观看视频网站免费| 美女国产视频在线观看| 伦理电影免费视频| 王馨瑶露胸无遮挡在线观看| 精品人妻熟女av久视频| 国产精品久久久久久久久免| 日日啪夜夜爽| 成年av动漫网址| 成年女人在线观看亚洲视频| av视频免费观看在线观看| 日韩,欧美,国产一区二区三区| 制服丝袜香蕉在线| 少妇人妻一区二区三区视频| 一级片'在线观看视频| 欧美一区二区亚洲| 97热精品久久久久久| 一级黄片播放器| 联通29元200g的流量卡| 精品少妇黑人巨大在线播放| 纵有疾风起免费观看全集完整版| 亚洲欧美成人综合另类久久久| 欧美一区二区亚洲| 免费观看的影片在线观看| 嘟嘟电影网在线观看| 欧美变态另类bdsm刘玥| 国产av码专区亚洲av| 欧美bdsm另类| 国产精品三级大全| 亚洲国产最新在线播放| 建设人人有责人人尽责人人享有的 | 成年人午夜在线观看视频| 国产精品蜜桃在线观看| 国产日韩欧美在线精品| 精品国产露脸久久av麻豆| 欧美日韩精品成人综合77777| av一本久久久久| 18禁裸乳无遮挡免费网站照片| 婷婷色av中文字幕| 精品亚洲成国产av| 人体艺术视频欧美日本| 日韩中字成人| 亚洲国产精品一区三区| 国产亚洲精品久久久com| 亚洲av在线观看美女高潮| h视频一区二区三区| 成人亚洲欧美一区二区av| 国产亚洲5aaaaa淫片| 18禁裸乳无遮挡动漫免费视频| 男男h啪啪无遮挡| 美女国产视频在线观看| 人人妻人人添人人爽欧美一区卜 | 99久久精品一区二区三区| 亚洲成人av在线免费| 久久精品国产自在天天线| 久久影院123| 人妻少妇偷人精品九色| 一级爰片在线观看| 99视频精品全部免费 在线| 国内揄拍国产精品人妻在线| 日本av手机在线免费观看| 久久人人爽人人片av| 一级毛片aaaaaa免费看小| 你懂的网址亚洲精品在线观看| av又黄又爽大尺度在线免费看| 免费观看的影片在线观看| 尤物成人国产欧美一区二区三区| 老司机影院毛片| 九九久久精品国产亚洲av麻豆| 乱系列少妇在线播放| 内射极品少妇av片p| 中国三级夫妇交换| 性色av一级| 精品国产露脸久久av麻豆| 激情 狠狠 欧美| 日日啪夜夜爽| 日日啪夜夜撸| 国产淫片久久久久久久久| 在线精品无人区一区二区三 | 久久久精品免费免费高清| 26uuu在线亚洲综合色| 亚洲av免费高清在线观看| 高清视频免费观看一区二区| 国产亚洲午夜精品一区二区久久| videos熟女内射| 一区二区三区精品91| 18禁裸乳无遮挡免费网站照片| 亚洲精品一二三| 免费播放大片免费观看视频在线观看| 51国产日韩欧美| 亚洲成色77777| 噜噜噜噜噜久久久久久91| 国产乱人偷精品视频| 亚洲精品乱码久久久久久按摩| 久久 成人 亚洲| 国产欧美日韩精品一区二区| 亚洲欧洲国产日韩| 国产中年淑女户外野战色| 成人亚洲精品一区在线观看 | tube8黄色片| 国产黄频视频在线观看| 欧美精品亚洲一区二区| 欧美xxⅹ黑人| videossex国产| 日韩在线高清观看一区二区三区| 中文精品一卡2卡3卡4更新| 国产v大片淫在线免费观看| 人妻夜夜爽99麻豆av| 啦啦啦中文免费视频观看日本| 国产免费又黄又爽又色| 亚洲国产精品专区欧美| 久热久热在线精品观看| 国产极品天堂在线| 国产 精品1| 三级经典国产精品| 综合色丁香网| 久久毛片免费看一区二区三区| 亚洲av.av天堂| 三级国产精品片| 久久人妻熟女aⅴ| 亚洲,一卡二卡三卡| 80岁老熟妇乱子伦牲交| 亚洲av.av天堂| 男人狂女人下面高潮的视频| 国产永久视频网站| 国产亚洲精品久久久com| 看免费成人av毛片| 久久综合国产亚洲精品| 另类亚洲欧美激情| 亚洲国产欧美人成| 男人添女人高潮全过程视频| 97超视频在线观看视频| 97在线人人人人妻| 少妇人妻 视频| 一级黄片播放器| 天堂中文最新版在线下载| 久久 成人 亚洲| 蜜桃在线观看..| 亚洲精品色激情综合| 极品教师在线视频| 亚洲美女黄色视频免费看| 国产片特级美女逼逼视频| 伦理电影大哥的女人| 久久影院123| 男人添女人高潮全过程视频| 一本色道久久久久久精品综合| 美女视频免费永久观看网站| 亚洲欧美精品专区久久| 韩国av在线不卡| 午夜福利在线观看免费完整高清在| 日韩成人av中文字幕在线观看| a级一级毛片免费在线观看| 国产成人91sexporn| 免费看av在线观看网站| 亚洲精品,欧美精品| 亚洲欧美中文字幕日韩二区| 亚洲第一区二区三区不卡| 美女福利国产在线 | 亚洲欧洲日产国产| 精品久久久噜噜| 国产伦精品一区二区三区视频9| 建设人人有责人人尽责人人享有的 | 日韩中文字幕视频在线看片 | 多毛熟女@视频| 国产 一区 欧美 日韩| 五月伊人婷婷丁香| 美女视频免费永久观看网站| 国产精品成人在线| 青春草国产在线视频| 我的老师免费观看完整版| 丰满少妇做爰视频| 国产精品一区二区三区四区免费观看| 久久久久久久精品精品| 精品少妇黑人巨大在线播放| 视频中文字幕在线观看| 久久久久久久久久成人| 少妇裸体淫交视频免费看高清| 国产高清三级在线| 久久久久久伊人网av| 欧美极品一区二区三区四区| 久久精品国产自在天天线| 国产69精品久久久久777片| 男女啪啪激烈高潮av片| a 毛片基地| 高清午夜精品一区二区三区| 最近手机中文字幕大全| 高清午夜精品一区二区三区| 婷婷色综合www| 亚洲经典国产精华液单| 99久久综合免费| 国产一区二区三区综合在线观看 | 九九在线视频观看精品| 性色avwww在线观看| 久久久久久久久久久免费av| 国产精品久久久久久av不卡| 性高湖久久久久久久久免费观看| 毛片一级片免费看久久久久| 波野结衣二区三区在线| 女人十人毛片免费观看3o分钟| 久久久久久久久久成人| 精品少妇久久久久久888优播| 久久毛片免费看一区二区三区| 少妇的逼好多水| 99热这里只有是精品50| 欧美精品国产亚洲| 久久婷婷青草| 亚洲欧洲日产国产| 男女无遮挡免费网站观看| 爱豆传媒免费全集在线观看| 国产成人精品一,二区| www.色视频.com| 午夜精品国产一区二区电影| 最新中文字幕久久久久| 蜜桃久久精品国产亚洲av| 国产 一区精品| 美女高潮的动态| 国产黄色免费在线视频| 国产视频内射| 国产 一区精品| 超碰97精品在线观看| 自拍偷自拍亚洲精品老妇| 最近的中文字幕免费完整| 国产成人精品久久久久久| 欧美日韩国产mv在线观看视频 | 国产精品99久久99久久久不卡 | 寂寞人妻少妇视频99o| 春色校园在线视频观看| 在线看a的网站| 热99国产精品久久久久久7| 一级毛片黄色毛片免费观看视频| 99久国产av精品国产电影| av.在线天堂| 能在线免费看毛片的网站| 黑丝袜美女国产一区| 欧美成人一区二区免费高清观看| 国产av码专区亚洲av| 插阴视频在线观看视频| 日本黄大片高清| 在现免费观看毛片| 日韩人妻高清精品专区| 国产中年淑女户外野战色| 亚洲精品日韩在线中文字幕| 国产69精品久久久久777片| 久久99蜜桃精品久久| 久久精品久久久久久久性| 自拍偷自拍亚洲精品老妇| 韩国高清视频一区二区三区| 精华霜和精华液先用哪个| 欧美 日韩 精品 国产| 日本午夜av视频| 久久久久久久大尺度免费视频| 国产一区二区三区av在线| 超碰97精品在线观看| 欧美日韩视频精品一区| 狂野欧美激情性bbbbbb| 国产熟女欧美一区二区| 亚洲精品久久午夜乱码| 日本一二三区视频观看| 高清毛片免费看| av在线观看视频网站免费| 国产亚洲精品久久久com| 内射极品少妇av片p| 欧美亚洲 丝袜 人妻 在线| 校园人妻丝袜中文字幕| 丝袜喷水一区| 人体艺术视频欧美日本| 欧美精品国产亚洲| 国产深夜福利视频在线观看| 免费人妻精品一区二区三区视频| 插阴视频在线观看视频| 亚洲精品一二三| 99热网站在线观看| 一级黄片播放器| 久久人妻熟女aⅴ| 久久6这里有精品| 亚洲精华国产精华液的使用体验| 丰满人妻一区二区三区视频av| 特大巨黑吊av在线直播| 日韩欧美 国产精品| 午夜福利视频精品| 中国美白少妇内射xxxbb| 久久久久视频综合| 国产精品久久久久久久久免| 国产乱人视频| 性色avwww在线观看| 国产一区二区三区综合在线观看 | 免费观看性生交大片5| 少妇的逼水好多| 欧美少妇被猛烈插入视频| 国产午夜精品一二区理论片| 久久综合国产亚洲精品| h日本视频在线播放| 精品久久久精品久久久| 身体一侧抽搐| 51国产日韩欧美| 亚洲欧美精品专区久久| 高清毛片免费看| 色吧在线观看| 青春草视频在线免费观看| a级毛片免费高清观看在线播放| 国产又色又爽无遮挡免| 久久精品久久精品一区二区三区| 亚洲成人av在线免费| av不卡在线播放| 精品人妻偷拍中文字幕| 免费看日本二区| 国产伦精品一区二区三区视频9| 久久久a久久爽久久v久久| 九色成人免费人妻av| 亚洲精品一二三| 91在线精品国自产拍蜜月| .国产精品久久| 久久久色成人| 久久久亚洲精品成人影院| 国产69精品久久久久777片| 26uuu在线亚洲综合色| 中文字幕人妻熟人妻熟丝袜美| 国产亚洲91精品色在线| 赤兔流量卡办理| 午夜免费鲁丝| 免费av不卡在线播放| 中文字幕精品免费在线观看视频 | 一级av片app| 亚洲欧洲国产日韩| 日韩视频在线欧美| 一级毛片久久久久久久久女| 久久国产精品大桥未久av | 成年女人在线观看亚洲视频| av视频免费观看在线观看| 伦理电影免费视频| 少妇高潮的动态图| 国产精品嫩草影院av在线观看| 亚洲av国产av综合av卡| 亚洲国产成人一精品久久久| 黑人高潮一二区| av视频免费观看在线观看| 日韩成人av中文字幕在线观看| 免费av不卡在线播放| 五月天丁香电影| 国产亚洲5aaaaa淫片| 久久久久久人妻| 国产欧美另类精品又又久久亚洲欧美| 在线播放无遮挡| 国产免费视频播放在线视频| av在线蜜桃| 99热这里只有是精品在线观看| 免费播放大片免费观看视频在线观看| 欧美97在线视频| 激情 狠狠 欧美| 五月开心婷婷网| 一本一本综合久久| 欧美日韩在线观看h| 久久精品国产鲁丝片午夜精品| 2018国产大陆天天弄谢| 亚洲欧美日韩东京热| 最近手机中文字幕大全| 日产精品乱码卡一卡2卡三| 熟妇人妻不卡中文字幕| 国产精品免费大片| www.av在线官网国产| 亚洲精品国产av成人精品| 午夜日本视频在线| 丝瓜视频免费看黄片| 九色成人免费人妻av| 亚洲久久久国产精品| 一区二区三区乱码不卡18| 亚洲激情五月婷婷啪啪| 亚洲不卡免费看| 久久久国产一区二区| 伦精品一区二区三区| 最后的刺客免费高清国语| 男女边摸边吃奶| 国产91av在线免费观看| 国产精品免费大片| 精品酒店卫生间| 五月天丁香电影| 欧美日韩视频精品一区| 国产日韩欧美在线精品| 黄色怎么调成土黄色| 日本免费在线观看一区| 99热6这里只有精品| 草草在线视频免费看| av专区在线播放| 久久97久久精品| 亚洲第一区二区三区不卡| 美女高潮的动态| 最近最新中文字幕免费大全7| 蜜桃在线观看..| 亚洲婷婷狠狠爱综合网| 午夜日本视频在线| av黄色大香蕉| 亚洲国产精品一区三区| 熟女电影av网| 三级国产精品片| 久久久久久伊人网av| 久久久欧美国产精品| 直男gayav资源| 有码 亚洲区| 大香蕉久久网| 亚洲欧美一区二区三区国产| 哪个播放器可以免费观看大片| 99热这里只有是精品50| 日韩成人av中文字幕在线观看| 免费观看在线日韩| 一级av片app| 777米奇影视久久| 日韩国内少妇激情av| 在现免费观看毛片| 黄片wwwwww| 精品视频人人做人人爽| 久久国产亚洲av麻豆专区| av网站免费在线观看视频| 18禁动态无遮挡网站| 一边亲一边摸免费视频| 成人免费观看视频高清| 免费黄色在线免费观看| 精品久久久久久电影网| 欧美老熟妇乱子伦牲交| 日本一二三区视频观看| 成人黄色视频免费在线看| 黄色欧美视频在线观看| 一区二区三区四区激情视频| 国产爱豆传媒在线观看| 高清毛片免费看| 国产精品爽爽va在线观看网站| 大陆偷拍与自拍| 色视频www国产| 免费不卡的大黄色大毛片视频在线观看| 91精品一卡2卡3卡4卡| 亚洲va在线va天堂va国产| 91aial.com中文字幕在线观看| 国产日韩欧美在线精品| 欧美zozozo另类| 久久热精品热| av黄色大香蕉| 人人妻人人添人人爽欧美一区卜 | 丰满少妇做爰视频| 国产精品福利在线免费观看| 国产日韩欧美在线精品| 女人十人毛片免费观看3o分钟| 久久热精品热| 精品人妻一区二区三区麻豆| 99九九线精品视频在线观看视频| 成年美女黄网站色视频大全免费 | 国产中年淑女户外野战色| 七月丁香在线播放| 久久精品国产亚洲av涩爱| 在线免费十八禁| 精品国产三级普通话版| 91精品一卡2卡3卡4卡| 国内精品宾馆在线| 看非洲黑人一级黄片| 国产午夜精品一二区理论片| 日韩免费高清中文字幕av| 一区在线观看完整版| 久热这里只有精品99| 一级毛片我不卡| 亚洲熟女精品中文字幕| 午夜免费观看性视频| 欧美成人一区二区免费高清观看| 中文欧美无线码| 国产淫语在线视频| 一区二区三区免费毛片| 欧美日韩在线观看h| 国产欧美日韩精品一区二区| 欧美日韩国产mv在线观看视频 | av在线老鸭窝| 啦啦啦视频在线资源免费观看| freevideosex欧美| 亚洲第一av免费看| 日日摸夜夜添夜夜爱| 国产黄色免费在线视频| 国产成人精品一,二区| 美女福利国产在线 | 乱系列少妇在线播放| 七月丁香在线播放| 人妻制服诱惑在线中文字幕| 亚洲欧美日韩另类电影网站 | 亚洲图色成人| 欧美性感艳星| 91久久精品电影网| videos熟女内射| 亚洲,一卡二卡三卡| 汤姆久久久久久久影院中文字幕| 亚洲第一av免费看| 大片免费播放器 马上看| 精品人妻视频免费看| 秋霞伦理黄片| 夜夜骑夜夜射夜夜干|